ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2544

Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE

Sang-Cheol Bae1, Richard Dimelow 2, Beulah Ji 3, Regina Kurrasch 4, Saima Muzaffar 5, Raj Punwaney 4, David Roth 4, Paul Stober 4, Yeong-Wook Song 6, Wendy Xie 4 and Fengchun Zhang 7, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2GSK, Stevenage, United Kingdom, 3GSK, Uxbridge, Middlesex, United Kingdom, 4GSK, Collegeville, PA, 5GSK, Stevenage, Hertfordshire, 6Seoul National University Hospital, Seoul, Republic of Korea, 7Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: belimumab, Biologics, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Belimumab is approved as add-on therapy in active, autoantibody-positive SLE. Safety and efficacy up to 13 years has been reported in adults, but potential for rebound upon temporary discontinuation of belimumab has not been investigated. This study (BEL116027; NCT02119156) assessed the impact of temporary withdrawal of intravenous (IV) belimumab.

Methods: In this 52-week open-label study, adults with SLE who received belimumab 10 mg/kg IV for ≥6 months in open-label studies were recruited to three arms: treatment holiday (TH; 24-week belimumab withdrawal, reintroduction for 28 weeks); continuous belimumab (treatment control; TC), and long-term discontinuation (LTD) (Figure).
The primary endpoint was time to first SLE flare (SFI). Secondary endpoints included flare rates and evidence of rebound (SELENA-SLEDAI [SS] exceeding parent study baseline score, anytime post baseline to Week 24). Anti-drug antibodies (ADAs) and changes in immunoglobulins and B Cells were measured. Safety was monitored.
Due to slow enrollment the study was amended to reduce sample size; all analyses are descriptive.

Results: The ITT comprised 80 patients (TH: n=12, TC: n=29; LTD: n=39). The majority were female (88.8%), ≤45 years of age (71.3%), and had SS >3 at baseline in the parent study (97.5%). Day 0 disease activity, race and geographic distribution differed for LTD vs TC/TH. A higher proportion of LTD patients (8/39; 20.5%) had flares during screening for this study vs TH (1/12; 8.3%) or TC arms (0/29; 0%). Also, 41.0% of LTD patients were recruited from the US and 23.1% were White; TC and TH arms were recruited from China, Korea and Japan (100% Asian).   
The majority in the holiday phase did not flare and flare rate during this time (1.0) was comparable to TC (0.6) (Table 1). Flare rate was highest in LTD (2.1). There were 9 severe and 4 renal flares in LTD and none in TH/TC.
No TH patients rebounded; two TC and two LTD patients rebounded (Table 1).
Adverse event (AE) and serious AE (SAE) rates were higher in LTD vs TC (Table 2). There were no withdrawals due to AEs and no SAEs in the holiday phase.
No ADAs were detected. In all arms, median levels of anti-dsDNA remained suppressed and complement C3/C4 levels remained above baseline over 52 weeks. At Day 0, median immunoglobulin levels were below baseline relative to the parent study and remained decreased throughout for all arms. B Cell levels remained depleted in TC throughout; in TH and LTD, CD19, CD20, and naïve B Cell counts started to recover after 16 weeks off-treatment but rapidly decreased to minimal levels following restart (TH). No Grade 3/4 laboratory abnormalities were noted in the TH arm. A small proportion of patients in the TC and LTD arms had Grade 3/4 laboratory abnormalities.

Conclusion: Temporary (24-week) discontinuation of belimumab in patients with low disease activity did not appear to increase risk of SLE flares or rebound. Across 52 weeks, no ADAs were identified in any arm and the belimumab safety profile was consistent with previous reports. Small sample size and differences in Day 0 characteristics between LTD and TC arms limit the ability to draw inferences. 

Study funding: GSK. Medical writing support: C Brazaitis, PhD, Fishawack Indicia Ltd, UK (funded by GSK).

Figure. Study Design

Table 1. Efficacy endpoints -ITT-

Table 2. Summary of AEs -52-week study period-


Disclosure: S. Bae, None; R. Dimelow, GlaxoSmithKline, 1, 3; B. Ji, GlaxoSmithKline, 1, 3, 4; R. Kurrasch, GlaxoSmithKline, 1, 3; S. Muzaffar, GlaxoSmithKline, 1, 3; R. Punwaney, GlaxoSmithKline, 1, 3; D. Roth, GlaxoSmithKline, 1, 3, 4; P. Stober, GlaxoSmithKline, 1, 3; Y. Song, Astellas Pharma, Inc., 9; W. Xie, GlaxoSmithKline, 1, 3; F. Zhang, GlaxoSmithKline, 9.

To cite this abstract in AMA style:

Bae S, Dimelow R, Ji B, Kurrasch R, Muzaffar S, Punwaney R, Roth D, Stober P, Song Y, Xie W, Zhang F. Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/results-of-the-open-label-non-randomized-52-week-study-to-evaluate-treatment-holidays-and-rebound-phenomenon-after-treatment-with-belimumab-in-patients-with-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/results-of-the-open-label-non-randomized-52-week-study-to-evaluate-treatment-holidays-and-rebound-phenomenon-after-treatment-with-belimumab-in-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology